Browsing Category
Healthcare Industry News
2694 posts
Smith+Nephew shares fall as CFO John Rogers exits weeks after revenue outlook cut
Smith+Nephew finance chief John Rogers is leaving after the group cut its revenue outlook, adding leadership uncertainty to a difficult US Orthopaedics recovery.
Cochlear (ASX: COH) shares rebound as FY27 guidance tests recovery after historic sell-off
Cochlear profit fell 22%, but stronger second-half sales and A$330m-A$350m FY27 guidance sent ASX: COH higher as investors tested the recovery.
Suraksha Diagnostic shares jump 13% after Q1 profit rises 40%
Suraksha Diagnostic Limited delivered 21% Q1 FY27 income growth, 40% profit growth and a 36% EBITDA margin. A sharp post-results share-price rally now shifts attention to whether new centres and genomics can sustain the operating leverage.
ResMed’s FY27 guidance reset tests investor confidence in sleep-apnea device growth
ResMed’s FY27 guidance reset pressured RMD despite strong cash flow. Read how Astral, GLP-1 drugs, MatrixCare and buybacks shape the medtech story.
BillionToOne selloff shows how diagnostics investors are repricing growth after Q2
BillionToOne grew Q2 revenue 64%, yet BLLN sold off after guidance stayed unchanged. Read how diagnostics investors are repricing growth.
Molbio Diagnostics IPO puts India’s point-of-care testing model under market spotlight
Molbio Diagnostics IPO closed over 70 times subscribed. Read how Truenat, point-of-care testing and public-market scrutiny could shape its next phase.
Heart ablation is moving beyond heat and cold, and the medtech race is getting much bigger
Pulsed field ablation is changing atrial fibrillation treatment by using extremely short electrical pulses to disrupt targeted cardiac cells instead of relying primarily on heat or freezing. Boston Scientific, Medtronic, Abbott Laboratories and Johnson & Johnson now compete across multiple FDA-approved PFA platforms, while new trials are pushing the technology into persistent atrial fibrillation, broader lesion sets and potentially earlier treatment.
RadNet revenue rose 25%, yet shareholder profit nearly halved. Where did the earnings go?
RadNet, Inc. (NASDAQ: RDNT) delivered record second-quarter revenue and adjusted EBITDA, but higher other expenses, taxes and the profit allocated to noncontrolling interests overwhelmed the operating gain and cut net income attributable to common shareholders by 47.9%.
Teledyne Technologies to acquire Varex Imaging, adding photon counting X-ray detectors to its imaging portfolio
Teledyne is paying a 52% premium for Varex Imaging, taking the only independent commercial photon counting CT detector supplier as OEMs race to catch Siemens.
What the FDA authorization of Elanco CLiK Extra means for the New World screwworm response
FDA authorizes Elanco CLiK Extra for New World screwworm prevention. See its species coverage, evidence, restrictions and outbreak role.